Cargando…

COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barahona-Correa, Julián E, Rueda-Ortiz, Camilo, López, María-José, Gualtero, Sandra, Arevalo-Zambrano, Mónica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834623/ https://www.ncbi.nlm.nih.gov/pubmed/36643709 http://dx.doi.org/10.1177/2050313X221148548

Ejemplares similares

Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
por: Hladnik,1, Lindsay, et al.
Publicado: (2016)

Cytokine Release Syndrome Following Blinatumomab Therapy
por: Ojemolon, Pius E, et al.
Publicado: (2022)

Blinatumomab-associated vasculitis
por: Liau, MeiQi May, et al.
Publicado: (2017)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017)

Recent advances on blinatumomab for acute lymphoblastic leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk
por: Wo, Stephanie, et al.
Publicado: (2022)

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
por: Sigmund, Audrey M, et al.
Publicado: (2020)

The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
por: Marrapodi, Maria Maddalena, et al.
Publicado: (2022)

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
por: Wei, Andrew H., et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
por: Gökbuget, N, et al.
Publicado: (2016)

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
por: Semchenkova, Alexandra, et al.
Publicado: (2022)

Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab
por: So, Wonhee, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma
por: Hijazi, Youssef, et al.
Publicado: (2018)

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
por: Clements, John David, et al.
Publicado: (2019)

Blinatumomab-induced T cell activation at single cell transcriptome resolution
por: Huo, Yi, et al.
Publicado: (2021)

Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia'
por: Tong, W H
Publicado: (2016)

Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review)
por: Queudeville, Manon, et al.
Publicado: (2021)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ueda, Tomoaki, et al.
Publicado: (2022)

Blinatumomab as bridging therapy in paediatric B‐cell acute lymphoblastic leukaemia complicated by invasive fungal disease
por: Yeoh, Daniel K., et al.
Publicado: (2022)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
por: Wang, Songmi, et al.
Publicado: (2023)

Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
por: Marschollek, Paweł, et al.
Publicado: (2022)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
por: Lee, Kum Ja, et al.
Publicado: (2016)

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells
por: Wu, Shang-Ju, et al.
Publicado: (2023)

Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab
por: Abdo, Yasmeen, et al.
Publicado: (2023)

Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
por: Ribera, Jose-Maria, et al.
Publicado: (2020)

Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis
por: Chen, Bin, et al.
Publicado: (2023)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
por: Portell, Craig A, et al.
Publicado: (2013)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2015)

Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab
por: Litzow, Mark R
Publicado: (2014)

Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol
por: Duffy, Caitlyn, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
por: Janardan, Sanyukta, et al.
Publicado: (2022)

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
por: Pourhassan, Hoda, et al.
Publicado: (2023)

Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia
por: Kobayashi, Yukio, et al.
Publicado: (2021)

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
por: Wullenkord, Ramona, et al.
Publicado: (2020)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gkndkmkjvqp0fhnh283ojiu9ek